<DOC>
	<DOCNO>NCT00000834</DOCNO>
	<brief_summary>To determine safety tolerance methotrexate HIV-infected patient . To determine dose effective modulating key marker immune activation . To determine dose suitable Phase II III evaluation HIV-infected patient . In HIV infection , complete immunological clearance foreign antigen occur , result chronic immune activation . Because chronic immune activation may contribute disease progression HIV infection , immunomodulators may therapeutic value early HIV disease prior development opportunistic infection . The clinical benefit methotrexate appear derive anti-inflammatory effect ; thus , may reduce state chronic immune activation .</brief_summary>
	<brief_title>A Phase I Study Methotrexate HIV Infection</brief_title>
	<detailed_description>In HIV infection , complete immunological clearance foreign antigen occur , result chronic immune activation . Because chronic immune activation may contribute disease progression HIV infection , immunomodulators may therapeutic value early HIV disease prior development opportunistic infection . The clinical benefit methotrexate appear derive anti-inflammatory effect ; thus , may reduce state chronic immune activation . Patients randomize receive methotrexate Dose 1 2 ( low dos ) 12 week , 8 week follow-up . If interim safety monitor viral burden result two cohort support continuation , third cohort patient receive methotrexate start Dose 2 first 2 week , Dose 3 next 2 week , Dose 4 remain 8 week , 8 week follow-up . AS PER AMENDMENT 1/10/97 : The Dose 1 ( low dose ) eliminate ; first 10 patient assign next high dose . Depending upon result interim safety data , next cohort enter escalate dose regimen . Also per amendment , patient receive zidovudine lamivudine 30 day prior initiation methotrexate , 12 week methotrexate administration , 8 week follow-up .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiemetics antidiarrheal . Acetaminophen . Oral hypoglycemic agent . PER AMENDMENT 5/15/96 : Stable dose antiretroviral ( must stable least 1 month prior study entry ) . [ AS PER AMENDMENT 1/10/97 : Combination zidovudine/lamivudine zidovudine alone . ] Patients must : HIV seropositivity . CD4 count &gt; = 300 cells/mm3 . No AIDSdefining condition . Exclusion Criteria Coexisting Condition : Patients follow symptom condition exclude : Current positive PPD . Concurrent Medication : Excluded : Immunosuppressive immunomodulatory drug . Chronic nonsteroidal antiinflammatory agent . Newly initiate antiretrovirals . Bone marrow suppressive drug ( e.g. , TMP/SMX ) . Concurrent Treatment : AS PER AMENDMENT 1/10/97 : Excluded : Antiretroviral therapy combination zidovudine/lamivudine zidovudine alone ; initiation antiretroviral therapy plan patient methotrexate . Patients follow prior condition exclude : Prior malignancy . Prior mucocutaneous herpes infection require antiviral therapy [ AS PER AMENDMENT 7/31/96 : Prior mucocutaneous herpes infection require systemic treatment antiviral agent ( e.g. , acyclovir ) ; history topical antiviral therapy permit ] . Anergic DTH skin test within past month ( PER AMENDMENT 5/15/96 : patient positive DTH skin test unable receive HIV1 skin test allergy insect , bee sting , etc. , remain eligible study enrollment ) . Inflammatory bowel disease , peptic ulcer disease , obesity combine insulinrequiring diabetes , liver disease , chronic renal disease within past 6 month . Positive HBsAg hepatitis C antibody within past 2 week . Chest radiograph within past 60 day show cavity disease , infiltrate , scar prior disease would preclude diagnosis new infectious process druginduced pneumonitis . AS PER AMENDMENT 1/10/97 : History intolerance zidovudine lamivudine . Prior Medication : Excluded : Prior chemotherapy malignancy . Prior Treatment : Excluded : Prior radiotherapy malignancy . Alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Disease Progression</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>